Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(7 sites)

United States

University of Miami, Miami, Florida

AdventHealth Orlando, Orlando, Florida

Roswell Park Cancer Institute, Buffalo, New York

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania

Lifespan Health System Rhode Island Hospital, Providence, Rhode Island